IDXX 145.16 Idexx Laboratories $IDXX Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 3:13 AM

IDXX 145.16 Idexx Laboratories $IDXX Hit a 52 week high of 146.00 Currently at 145.16 -0.75 -0.51% With a day low of 143.86 and a total volume of 995,000.

IDXX Idexx Laboratories Recent Headline News

Idexx Laboratories Has Returned 17.5% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Nov 05, 9:25AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 2 weeks, Idexx Laboratories has returned 17.52% as of today's recent price of $143.98.
IDXX: 145.16 (-0.75)

Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 186.15 (-3.73), GE: 26.41 (+0.05), BMRN: 83.91 (-0.12), IDXX: 145.16 (-0.75), GSK: 44.91 (+0.16), NVS: 91.76 (-0.27)

IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:57AM CDT
IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue?
IDXX: 145.16 (-0.75)

IDEXX Tops Q3 Earnings and Revenues; Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:10PM CDT
Since the news release, IDEXX's (IDXX) share price has climbed 9.8% to eventually close at $138.76 yesterday.
ATEC: 1.39 (-0.06), EW: 122.76 (-0.81), IDXX: 145.16 (-0.75), ANGO: 16.95 (+0.10)

Today's Strong And Under The Radar Stock Is Idexx Laboratories (IDXX)
at The Street - Tue Oct 28, 8:51AM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 145.16 (-0.75)

IDEXX Laboratories, Inc. Is as Fit as a Butcher's Dog
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 24, 6:56PM CDT
Shares of IDEXX Laboratories jumped 7% today after reporting a solid third quarter, raising 2014 guidance, and issuing 2015 guidance that looks even better. The stock of the animal health-test provider soared to a 52-week and all-time high. ...
IDXX: 145.16 (-0.75)

Idexx Laboratories Set to Possibly Pullback After Yesterday's Rally of 7.00%
Comtex SmarTrend(R) - Fri Oct 24, 4:12PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $130.06 to a high of $140.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $126.42 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 145.16 (-0.75)

Idexx beats Street 3Q forecasts
Automated Insights - Fri Oct 24, 6:27AM CDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported net income of $52.1 million in its third quarter.
IDXX: 145.16 (-0.75)

IDEXX Laboratories Announces Third Quarter Results
PR Newswire - Fri Oct 24, 6:00AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that revenues for the third quarter of 2014 increased 13% versus the prior year period to $384 million. Organic revenue growth1 for the third quarter of 2014 versus the prior year period was also 13%, or 11% normalized for changes in distributor inventory2. Earnings per diluted share ("EPS"

for the quarter ended September 30, 2014 increased 21% from the prior year period to $1.03. Adjusted EPS3 for the quarter was $1.05.
IDXX: 145.16 (-0.75)

Oracle Enterprise Manager Enables Seamless IT Management and Visibility for IDEXX Laboratories
Marketwired - Wed Oct 15, 7:04AM CDT
Oracle (NYSE: ORCL)
IDXX: 145.16 (-0.75), ORCL: 39.94 (+0.13)

IDEXX Laboratories to Release 2014 Third Quarter Financial Results
PR Newswire - Tue Oct 14, 12:45PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has scheduled the release of its 2014 third quarter financial results for Friday, October 24, 2014 at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
IDXX: 145.16 (-0.75)

IDEXX Laboratories Poised on Strong CAG Growth Globally - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 5:40PM CDT
On Oct 7, 2014, we updated our research report on IDEXX Laboratories, Inc. (IDXX).
HNSN: 0.83 (-0.07), EW: 122.76 (-0.81), IDXX: 145.16 (-0.75), HOLX: 26.21 (-0.37)

Idexx Laboratories (IDXX) Marked As A Barbarian At The Gate
at The Street - Wed Oct 01, 2:02PM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
IDXX: 145.16 (-0.75)

IDEXX Announces Several Milestones in its US All-Direct CAG Distribution Strategy
PR Newswire - Wed Oct 01, 9:29AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that it had selected United Parcel Service (UPS) to provide third party logistic services in support of its strategy to go all-direct with US companion animal veterinary practices. This agreement builds on IDEXX's distribution and logistics capability, and provides for five warehouse and shipping locations strategically located across the US, three of which are provided by UPS' third party logistics services.
IDXX: 145.16 (-0.75)

Idexx Laboratories Shares Down 11.7% Since SmarTrend's Sell Call (IDXX)
Comtex SmarTrend(R) - Mon Sep 22, 5:23PM CDT
SmarTrend identified a Downtrend for Idexx Laboratories (NASDAQ:IDXX) on July 28th, 2014 at $129.81. In approximately 2 months, Idexx Laboratories has returned 11.66% as of today's recent price of $114.67.
IDXX: 145.16 (-0.75)

Watch for Idexx Laboratories to Potentially Rebound After Falling 2.51% Yesterday
Comtex SmarTrend(R) - Fri Sep 19, 4:21PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $116.47 to a high of $121.12. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $119.68 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IDXX: 145.16 (-0.75)

Idexx Laboratories (IDXX) Shows Signs Of Being Water-Logged And Getting Wetter
at The Street - Fri Sep 19, 9:02AM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
IDXX: 145.16 (-0.75)

IDEXX Laboratories names Jacqueline L. Studer as corporate VP
M2 - Fri Sep 19, 6:31AM CDT
Healthcare company IDEXX Laboratories (NasdaqGS:IDXX) said on Friday that Jacqueline L. Studer has been named as its corporate vice president, general counsel and secretary.
IDXX: 145.16 (-0.75)

IDEXX Laboratories Names Jacqueline L. Studer Corporate Vice President and General Counsel
PR Newswire - Thu Sep 18, 4:31PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announces today the appointment of Jacqueline L. Studer as Corporate Vice President, General Counsel and Secretary, effective September 1. Ms. Studer leads the Legal, Compliance, Regulatory Affairs and Quality Assurance groups.
IDXX: 145.16 (-0.75)

Global Veterinary Diagnostics Market 2014-2018 Featuring Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech & Zoetis
M2 - Thu Sep 04, 3:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k9m9mv/global_veterinary) has announced the addition of the "Global Veterinary Diagnostics Market 2014-2018" report to their offering. The Global Veterinary Diagnostics market to grow at a CAGR of 8.10 percent over the period 2013-2018. Veterinary diagnostics include various tests, which are used to detect diseases in animals. Veterinarians, pet owners, livestock producers, and biomedical researchers are mainly availing these diagnostic services. Major diagnostic methods include molecular testing (Deoxyribonucleic Acid/Ribonucleic Acid testing), immunodiagnostics, clinical chemistry, and hematology. These tests are executed through blood, urine, tissue, and feces samples from animals. The Global Veterinary Diagnostics market is expected to grow steadily during the forecast period of 2014-2018 because of the presence of early animal molecular diagnostics tests that execute rapid diagnosis for a wide variety of diseases. Advances in technology in laboratory equipment have led to tests to detect challenging diseases in animals. According to the report, the increasing diagnosis of diseases in animals as a result of advances in technology is one of the major drivers of this market. The outbreak of diseases among animals and their spread to humans, leading to the threat of epidemics worldwide, is a major concern. Further, the report states that one of the major challenges in the market is low animal healthcare expenditure because of the economic downturn. This has caused changes in concern over the health of animals, resulting in negligence in their treatment. To calculate the market size, the report considers the revenue generated through the following five segments: - Clinical Chemistry - Hematology Analyzers - Molecular Diagnostics - Immunodiagnostics - Diagnostics Imaging Key Vendors - Abaxis - Heska - IDEXX Laboratories - Mindray Medical - VCA Antech - Zoetis Other Prominent Vendors - Neogen - Thermo Fisher Scientific - Virbac For more information visit http://www.researchandmarkets.com/research/k9...veterinary
ABAX: 51.63 (-2.21), NEOG: 43.01 (-0.83), IDXX: 145.16 (-0.75)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Redwood and SAP Partner on Secure File Transfer

Redwood Advances SAP Interiors with New File Solution October 26, '26 is now a landmark for Redwood Software. They've just rolled out their SAP Managed File Transfer solution. Got the brainpower behind Redwood and SAP operating together here, and they're offering this to enterprises aimed at optimizing their file-based workflow. If you're scratching your head just hearing...

Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Community in Shock After Fatal Bakersfield Shooting

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Tennessee's Bold Lung Cancer Trial Signals Innovation

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Clarins Dazzles Austin with Skin Longevity Event

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...